ENDO: Once-Weekly Basal Insulin Fc Promising for T2DM
In phase 2 trial, fewer hypoglycemic events (≤70 mg/dL) seen in both BIF dosing groups compared with insulin degludec
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.